Independent, evidence-based peptide science intelligence. Our editorial team combines expertise in peptide chemistry, molecular pharmacology, and biotech industry analysis.
Eli Lilly's triple-agonist peptide retatrutide delivered up to 30.3% average body weight loss in the pivotal TRIUMPH-1 Phase 3 trial — results that put peptide therapeutics on par with bariatric surgery for the first time.
Kither Biotech's inhaled peptide KIT2014 just cleared Phase 1 testing. The drug targets COPD through a novel cAMP signaling mechanism — and it could change how we think about delivering peptides to the lungs.
The FDA will hold an advisory committee meeting in July 2026 to review 7 peptides for compounding pharmacy use, while removing 12 from the restrictive Category 2 bulks list. The move follows direct pressure from Health Secretary RFK Jr. and the MAHA movement, marking the most significant peptide regulatory shift in a decade.
Vedana Therapeutics emerges from stealth with $46M Series A to develop anti-PACAP antibody therapies for migraine prevention. Led by the veterans who built the CGRP drug class, the startup targets a neuropeptide pathway that could help the 50%+ of patients who don't respond to current treatments.
A new meta-analysis of 36 randomized controlled trials reveals GLP-1 receptor agonists cause 1.5 kg of lean body mass loss — 28% of total weight reduction. The findings raise urgent questions about body composition monitoring in the era of widespread GLP-1 prescribing.
Sciwind Biosciences' cAMP-biased GLP-1 analogue ecnoglutide shows no clinically significant drug-drug interactions with rosuvastatin or digoxin in a Phase 1 study, while delivering 11.2% weight loss over 14 weeks. The findings support the peptide's march toward regulatory filing after two positive Phase 3 trials published in The Lancet.
The European Commission has approved CinnaGen's Zandoriah, the first teriparatide biosimilar for osteoporosis. What does this regulatory milestone mean for the broader peptide therapeutics and biosimilar manufacturing landscape?
Oral peptides will replace injectables for some classes — GLP-1s are leading — but not most. The economics of 1% bioavailability mean oral delivery only works for large-market, high-price peptides. For many, a once-weekly injection is more convenient than a daily fasting pill.
FDA approved 28 peptide drugs from 2020 to mid-2026. Linear peptides dominate (61%), but macrocycle INDs surged 140% in 2 years. The 36% CRL rate for peptide NDAs is a warning: CMC rehearsal is the cheapest insurance against a 12-month approval delay.
Peptide purification accounts for 30-50% of API cost and remains the manufacturing bottleneck no one discusses. This guide covers RP-HPLC, SMB, nanofiltration, and the emerging methods that could reshape purification economics.
CagriSema — Novo Nordisk's semaglutide/cagrilintide combo — achieved 15.6% weight loss in Phase II with complementary GLP-1 and amylin pathway engagement. Phase III data expected H2 2026 will determine whether it can compete with tirzepatide's 21.1%.
Peptide stability testing errors — from testing only at pH 7.4 to filing without forced degradation data — are the leading cause of peptide CMC Complete Response Letters. Experienced developers begin stability studies at lead optimization, not after formulation lock.
Matrixyl sends a fake distress signal to fibroblasts using a five-amino-acid collagen fragment called KTTKS. Here is the full molecular mechanism, clinical data, and what formulators get wrong about concentration and delivery.
Clean skincare brand Mad Hippie launches the Wrinkle Relaxing Eye Treatment ($34.99) — five peptide complexes including Syn-Ake, Argireline Amplified and Matrixyl Synthe'6 in a retinol- and Botox-free eye cream.
